Coherus Biosciences Email Format

Biotechnology Research
201-500 employees
Redwood City, CA, USA

Coherus Biosciences is a commercial-stage oncology company developing and marketing innovative cancer therapies, including its approved PD-1 inhibitor and a pipeline targeting liver, lung, and head and neck cancers.

Find contacts at Coherus Biosciences

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

firstinitiallast@coherus.com

Company Overview

Industry
Biotechnology Research
Founded
2010
Headquarters
Redwood City, CA, USA
Revenue
$25M-$50M
FUNDING Stage
Public
Key Executives
Dennis M. Lanfear (President & Chief Executive Officer), Bryan McMichael (Chief Financial Officer), Richard L. Hameister (Chief Technical Officer)

Tech Stack

Salesforce

CRM

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Coherus Biosciences?

Coherus Biosciences uses the firstinitiallast format, so Jane Smith would be jsmith@coherus.com.

What approved product does Coherus Biosciences currently market in the United States?

Coherus Biosciences markets LOQTORZI (toripalimab-tpzi), an FDA-approved PD-1 inhibitor indicated for first-line and later-line treatment of recurrent or metastatic nasopharyngeal carcinoma, making it the only approved therapy for that indication in the US.

How does Coherus Biosciences structure its immuno-oncology pipeline beyond LOQTORZI?

Beyond LOQTORZI, Coherus Biosciences is advancing two additional pipeline candidates: tagmokitug, an anti-CCR8 antibody in Phase 1 and Phase 2 trials across multiple tumor types, and casdozokitug, an IL-27 antagonist in a Phase 2 study for hepatocellular carcinoma.

Who founded Coherus Biosciences and currently leads the company?

Dennis M. Lanfear co-founded Coherus Biosciences in 2010 and continues to serve as President and Chief Executive Officer. He presented the company's strategic oncology vision at The Citizens Life Sciences Conference in March 2026.

Can Clay help me find and verify contact information for Coherus Biosciences employees?

Yes, Clay can enrich your prospect list with verified Coherus Biosciences employee emails and other contact details, saving you time when building outreach sequences targeting the company's oncology or commercial teams.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles